14 th call for research projects within the ERA-NET JPIAMR-ACTION
“Disrupting drug Resistance Using Innovative Design” DRUID
The DRUID Call aims to improve the treatment of bacterial and fungal infections (including coinfection) and/or the prevention of the emergence/spread of resistance in humans, animals or plants through the improvement of the efficacy, specificity, delivery, combinations and/or repurposing of drugs and plant protection agents.
Who can apply:
CZ: universities, public research institutes and/or another entities classified as research organisations.
(More specification in national rules of each participating country.)
Eligible countries: Belgium, Canada, Czech Republic, Denmark, Estonia, France, Germany, Hungary, Israel, Italy, Latvia, Lithuania, Moldova, Poland, Spain, Sweden, Switzerland, United Kingdom
Eligibility rules for the consortia are:
- The consortium must include a minimum of three (3) eligible partners asking for funding from three (3) different eligible countries (including at least two amongst EU Member States or Associated Countries).
- The consortium can include a maximum of six (6) project partners (including non-funded partners). The maximum number of partners can be increased to seven (7) if at least a partner from an under-represented country (including LMICs) or a company is included in the consortium.
Duration of the grant:
max. 3 years
Budget:
Each country will fund its own approved project partners.
CZ allocation: 500.000 €
The aid intensity for activities carried out by a research organisation might be at the level of 100 % (100 % for fundamental/basic research activities, 50 % for applied research activities and 25 % for experimental development activities)
Timetable:
Opening: 11. 1. 2022
Deadline (pre-proposals): 8. 3. 2022
Full proposal invitations: 30. 6. 2022
Deadline (full proposals): 5. 7. 2022
Publication of results: 18. 11. 2022
Topics of the call:
Your proposal should focus on licenced antimicrobial agents(antibiotics/antifungals) or agents under pre-clinical and/or early clinical development, and should address at least one of the following topics:
- Improvement of drug/plant protection agent efficacy and/or specificity through chemical modifications (including hit to lead optimisation);
- Drug/plant protection agent repurposing;
- Optimisation of drug/plant protection agent combinations, alone or with adjunct therapies (including therapeutic vaccines);
- Design and implementation of new strategies (including optimisation of drug doses) for improved application, efficacy and delivery of single or combinations of antimicrobials;
- Design and implementation of innovative tools, including novel chemistry and/or new materials for improved application, efficacy and delivery of antimicrobials.
Your proposal can include the development of new mathematical models, optimisation of antimicrobial combinations and/or conditions for clinical/agricultural use, or treatment protocols based on combination therapy, personalised medicine and PK/PD. Studies may include companion diagnostics in the optimisation of treatment strategies.
Type of studies/ experimental approaches:
- In silico, in vitro, in vivo and/or
- Preclinical and clinical studies in human and in all veterinary settings, and/or
- Studies in crop/plant settings, including field studies
Eligible costs:
- Personal costs
- Consumables
- Equipment
- Indirect costs
Oddělení projektové podpory nabízí možnost propagace expertízy pracovišť LF MU prostřednictvím vložení informací do portálu Crowdhelix ve vztahu k této nebo budoucím výzvám. Crowdhelix je platforma umožňující vytváření vazeb mezi výzkumnými pracovišti a inovativními společnostmi prostřednictvím zveřejnění nabídky/poptávky expertízy pro řešení společných mezinárodních projektů.